A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

NCT00405756 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

459

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed Multiple Myeloma

Interventions

DRUG: Lenalidomide: Double-blind Induction
DRUG: Melphalan
DRUG: Prednisone
DRUG: Aspirin
DRUG: Placebo
DRUG: Lenalidomide: Double-blind Maintenance
DRUG: Lenalidomide: Open-label

Sponsor

Celgene Corporation